Viroblock's nose spray shows anti-flu effect in vivo

Viroblock SA says that its first-generation VCCD Tech antiviral nasal spray formulation is active against human influenza. The agent's  patented Cholesterol Catalytic Depletion Technology inactivates  enveloped viruses during the extra-cellular phase, by altering and  destabilizing cholesterol-rich viral envelopes.

The two preclinical studies exposed ferrets to influenza A  Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were  conducted by Retroscreen Virology, a recognized specialist in the  research and testing of antiviral compounds and vaccines. Both the  direct inoculation and the natural transmission protocols confirmed the  effectiveness and the value of the antiviral nasal spray.

These in vivo tests support all laboratory in vitro studies to date and  demonstrate that VCCD Tech represents a breakthrough for inactivating a  number of enveloped viruses and their strains, Viroblock noted.